|
Flecainide in Treating Patients With Chronic Neuropathic Pain Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Flecainide in Treating Patients With Chronic Neuropathic Pain conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Flecainide in Treating Patients With Chronic Neuropathic Pain Clinical research trials and Flecainide in Treating Patients With Chronic Neuropathic Pain medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Flecainide in Treating Patients With Chronic Neuropathic Pain. Flecainide in Treating Patients With Chronic Neuropathic Pain Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Flecainide in Treating Patients With Chronic Neuropathic Pain clinical trial. Test subjects typically obtain the finest healthcare available for their Flecainide in Treating Patients With Chronic Neuropathic Pain condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "F" Clinical Trials Conditions > Flecainide in Treating Patients With Chronic Neuropathic Pain  Flecainide in Treating Patients With Chronic Neuropathic Pain
Flecainide in Treating Patients With Chronic Neuropathic Pain
For Condition: Pain
Status: No longer recruiting
Sponsor(s): Eastern Cooperative Oncology Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: Flecainide therapy may help patients with neuropathic pain live more comfortably. PURPOSE: Phase II trial to study the effectiveness of flecainide in treating patients with chronic neuropathic pain from cancer or AIDS.
Details: OBJECTIVES: - Investigate the effectiveness of flecainide in the management of neuropathic pain. OUTLINE: Patients are given a brief pain inventory (BPI) form to assess their pain upon enrollment in the study. Following a 7 day stabilization period, flecainide is administered. One capsule of flecainide is given twice a day on days 8-10, two capsules are given twice a day on days 11-14 and three capsules are given twice a day on days 15-21. BPI forms are completed on days 8, 15 and 22 to assess neuropathic pain. PROJECTED ACCRUAL: A total of 7-20 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 19 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Chronic neuropathic pain with diagnosis of cancer or AIDS PATIENT CHARACTERISTICS: Age: - Over 18 Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - SGOT no greater than 2 times upper limit of normal (ULN) Renal: - Creatinine no greater than 2 times ULN Cardiovascular: - No clinical history of infarction or angina - No advanced heart failure - No sick sinus syndrome, intraventricular conduction disease, second or third degree AV block or arrhythmias requiring treatment (exception may be granted by cardiac consult) - No focal wall motion abnormalities - Ejection fraction at least 40% - Systolic blood pressure at least 90 mm Hg Other: - Must be able to take oral medication - No known allergy or adverse reaction to flecainide, mexilitene or any other type I antiarrhythmic drug - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - At least 2 weeks since prior chemotherapy that may cause neuropathy Endocrine therapy: - At least 2 weeks since prior corticosteroids Radiotherapy: - Not specified Surgery: - Not specified Other: - No tricyclic antidepressant treatment within past 2 weeks - No concurrent use of flecainide, mexiletene or any other type I antiarrhythmic drug
Total Enrollment:
Location and Contact Information:
Overall Study Official:
CharlesVon Gunten, Study Chair, Robert H. Lurie Cancer Center
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309-1016
United States
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792-0001
United States
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
United States
CCOP - Cedar Rapids Oncology Project
Cedar Rapids, Iowa, 52403-1206
United States
CCOP - Sioux Community Cancer Consortium
Sioux Falls, South Dakota, 57104
United States
CCOP - Kalamazoo
Kalamazoo, Michigan, 49007-3731
United States
Additional Information:
Study ID Numbers: CDR0000065544; ECOG-1Z95
Study Start Date:
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002996
Other Pain Studies:
1. Intrathecal Ziconotide Effectiveness and Safety Trial in Patients with Chronic Severe Pain
2. Combination Chemotherapy in Treating Pain in Patients With Hormone Refractory Metastatic Prostate Cancer
3. Valdecoxib in Treating Chronic Pain in Cancer Patients
4. Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy
5. Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
Related Studies:
Other Pain Clinical Trials
Other South Dakota Clinical Trials
Other Sioux Falls Clinical Trials
Flecainide in Treating Patients With Chronic Neuropathic Pain
|
|
|
|
|
|
|
|
